Clinical Trial Search

Primary: Mean Self-reported Adherence Score (%) Over a One-month Recall — 97.5; 98.2 percentage of adherence score — p=0.52

Primary: AIDS Clinical Trials Group (ACTG) 3-day Recall Measure of Doses Taken — 72.89; 75.46; 74.86; 77.33 percent with 100% adherence — p=0.12

Primary: Change in Tenofovir Diphosphate (TFV-DP) Drug Levels — 1230; 1108; 1887; 1084 fmol/punch — p=0.070

Primary: Mean Adherence, as Measured by Electronic Drug Monitors (EDM) — 96.5; 84.5; 96.4; 84.1 percentage of doses taken on time

Primary: Medication Adherence — 77.96; 80.13; 64.87; 76.13 Percentage of doses taken — p=.005

Primary: Feasibility of Retaining Study Participants Through the 3 Month Trial — 20; 21 Participants

Primary: Medication Adherence — 88.1; 96.6; 94.4 percentage of doses taken (pill count)

Primary: Intervention Feasibility as Measured by Number of Providers Agreeing to Participate — 6 Participants

Primary: Blood Pressure Medication Adherence — 396; 470 Participants — p=0.0103

Primary: Adherence to Statins — 0.55; 0.57; 0.58; 0.38 mMPR as a fraction — p=<.001

Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus - Type I Ribonucleic Acid (HIV-1 RNA) Levels Less Than (<) 50 Copies/mL at Week 12 — 24.4; 20.9…

Primary: Depression From (1) Clinician-Administered MADRS Measure, and (2) Participant Self-Report Ratings With BDI-1a — 17.8; 19.2; 19.7; 17.7 Units on a scale

Primary: Rate of Medication Adherence — 0.76; 0.79; 0.83 percentage of doses taken — p=0.78

Primary: Adherence Measured by Sensor by Percentage of Prescribed Medications Taken — 87.5 percentage of prescribed medication

Primary: Medication Adherence — 46.2; 42.1 percentage of days covered

Primary: Percentage of Adherent Participants — 65; 38 percentage of participants — p==0.004

Primary: Antipsychotic Medication Adherence — 63.9; 75.0 percentage of participants — p=0.03

Primary: Change in Treatment Non-adherence as Measured by the Tablets Routine Questionnaire (TRQ) (Past Month) — -23.6 percentage of medication not taken — p=<0.001

Primary: The Patients' Satisfaction With Chronic Obstructive Pulmonary Disease (COPD) Medical Treatments During a 12-month Observation Period — 64.2; 66.2; 67.1; 75.8 Unit on Scale

Primary: Antiretroviral Therapy (ART) Adherence (Self-reported 3-day Recall Measure) — 142; 139; 6; 12 participants

Primary: Number of Participants Who Reported Experiences With the ARICA Program — 12 Participants

Primary: Percent of Participants With Adherence at Month 6 — 91; 40 percent persistent on therapy — p=<0.05

Primary: Change in Treatment Adherence Within the Past Month as Measured by the Tablet Routines Questionnaire — -27.8 units on a scale — p=<.001

Primary: Time to Next Asthma or COPD Exacerbation up to 182 Days — 172; 161 days to first exacerbation

Primary: Medication Adherence — 21.6; 23.8 score on a scale

Primary: Analyze How Adherence to Treatment Using ASK-20 Questionnaire Influences Level of Asthma Control. — 34; 32 units on a scale — p=0.967

Primary: Feasibility of the Intervention - Number of Counseling Sessions — 2.92; 1 sessions

Primary: Measured MEMS Adherence- Number of Days With a Correct Number of Doses Taken — 15.14; 20.22 Days

Primary: Self-reported Adherence to Artemisinin-combination Therapy (ACT) Treatment — 61.5; 69.0; 64.1 percentage of participants

Primary: Adherence — 91.84; 88.61; 72.55 Percentage of medication taken